RudaCure, a 生物风投企业 developing treatments for intractable diseases, held a 技术转让 agreement signing ceremony with 翰林制药 Co., Ltd., a mid-sized company developing domestic 眼科 disease treatments, on the 13th for the 角膜溃疡 and 角膜损伤 treatment RCI001U.
RCI001U is a 管线 derived from the existing 干眼症治疗药 RCI001, and has demonstrated superior 角膜损伤 healing effects compared to existing 角膜 treatments. Through this agreement, RudaCure provides 翰林制药 with domestic production and sales rights to the technology and receives milestone payments including 临床试验 approvals.
Given the current absence of domestic drugs for 角膜损伤 treatment, RudaCure's RCI001U is being transferred after completing third-party confirmatory 疗效 testing along with non-clinical toxicology studies. It is expected that RudaCure and its strategic partner 翰林制药 will be able to respond swiftly to the 角膜损伤 treatment market where drugs are currently absent.
RudaCure had already completed the domestic 技术转让 of the 干眼症治疗药 RCI001 to 翰林制药 in April 2021, and by executing this additional indication development agreement, the network between the two companies has been further strengthened. Going forward, it is expected that continuous collaboration will be pursued not only for 干眼症 and 角膜损伤 treatments, but also for the development of various 眼科 treatments including 眼部 implants for 黄斑变性 treatment.
메디팜헬스 http://www.medipharmhealth.co.kr/news/article.html?no=88169 헬스코리아 뉴스 https://www.hkn24.com/news/articleView.html?idxno=331344 메디파나 https://www.medipana.com/article/view.php?news_idx=307266&sch_cate=D팜뉴스 https://www.pharmnews.com/news/articleView.html?idxno=217143
헤럴드경제 http://news.heraldcorp.com/view.php?ud=20230116000105
메디소비자뉴스 http://www.medisobizanews.com/news/articleView.html?idxno=103851
데일리팜 http://www.dailypharm.com/Users/News/NewsView.html?ID=296092
약업신문 https://www.yakup.com/news/index.html?mode=view&cat=12&nid=277798
